» Articles » PMID: 35881641

Antibiotic Persistence of Intracellular Brucella Abortus

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Human brucellosis caused by the facultative intracellular pathogen Brucella spp. is an endemic bacterial zoonosis manifesting as acute or chronic infections with high morbidity. Treatment typically involves a combination therapy of two antibiotics for several weeks to months, but despite this harsh treatment relapses occur at a rate of 5-15%. Although poor compliance and reinfection may account for a fraction of the observed relapse cases, it is apparent that the properties of the infectious agent itself may play a decisive role in this phenomenon.

Methodology/principal Findings: We used B. abortus carrying a dual reporter in a macrophage infection model to gain a better understanding of the efficacy of recommended therapies in cellulo. For this we used automated fluorescent microscopy as a prime read-out and developed specific CellProfiler pipelines to score infected macrophages at the population and the single cell level. Combining microscopy of constitutive and induced reporters with classical CFU determination, we quantified the protective nature of the Brucella intracellular lifestyle to various antibiotics and the ability of B. abortus to persist in cellulo despite harsh antibiotic treatments.

Conclusion/significance: We demonstrate that treatment of infected macrophages with antibiotics at recommended concentrations fails to fully prevent growth and persistence of B. abortus in cellulo, which may be explained by a protective nature of the intracellular niche(s). Moreover, we show the presence of bona fide intracellular persisters upon antibiotic treatment, which are metabolically active and retain the full infectious potential, therefore constituting a plausible reservoir for reinfection and relapse. In conclusion, our results highlight the need to extend the spectrum of models to test new antimicrobial therapies for brucellosis to better reflect the in vivo infection environment, and to develop therapeutic approaches targeting the persister subpopulation.

Citing Articles

A comparison between adjuvant and delivering functions of iron oxide and calcium phosphate nanoparticles, using a model protein against .

Goudarzi T, Abkar M, Fasihi-Ramandi M, Peikar M, Zamanzadeh Z Clin Exp Vaccine Res. 2025; 14(1):67-76.

PMID: 39927221 PMC: 11799579. DOI: 10.7774/cevr.2025.14.e3.


Reactivation of hidden-latent infection after doxycycline and streptomycin treatment in mice.

Sancho-Sanchez E, Garcia-Arteaga K, Granados-Chinchilla F, Artavia G, Alfaro-Alarcon A, Villalobos-Villalobos A Antimicrob Agents Chemother. 2025; 69(2):e0130224.

PMID: 39745377 PMC: 11823614. DOI: 10.1128/aac.01302-24.


The putative type 4 secretion system effector BspD is involved in maintaining envelope integrity of the pathogen .

Ketterer M, Chiquet P, Esposito M, Sedzicki J, Quebatte M, Dehio C mSphere. 2024; 9(11):e0023224.

PMID: 39387552 PMC: 11580434. DOI: 10.1128/msphere.00232-24.


Brucellosis: Unveiling the complexities of a pervasive zoonotic disease and its global impacts.

Khairullah A, Kurniawan S, Puspitasari Y, Aryaloka S, Silaen O, Yanestria S Open Vet J. 2024; 14(5):1081-1097.

PMID: 38938422 PMC: 11199761. DOI: 10.5455/OVJ.2024.v14.i5.1.


The (p)ppGpp synthetase Rsh promotes rifampicin tolerant persister cell formation in by regulating the type II toxin-antitoxin module .

Liu X, Wang P, Yuan N, Zhai Y, Yang Y, Hao M Front Microbiol. 2024; 15:1395504.

PMID: 38841069 PMC: 11150624. DOI: 10.3389/fmicb.2024.1395504.


References
1.
Mitchell G, Chen C, Portnoy D . Strategies Used by Bacteria to Grow in Macrophages. Microbiol Spectr. 2016; 4(3). PMC: 4922531. DOI: 10.1128/microbiolspec.MCHD-0012-2015. View

2.
Ko J, Splitter G . Molecular host-pathogen interaction in brucellosis: current understanding and future approaches to vaccine development for mice and humans. Clin Microbiol Rev. 2003; 16(1):65-78. PMC: 145300. DOI: 10.1128/CMR.16.1.65-78.2003. View

3.
Salcedo S, Marchesini M, Degos C, Terwagne M, von Bargen K, Lepidi H . BtpB, a novel Brucella TIR-containing effector protein with immune modulatory functions. Front Cell Infect Microbiol. 2013; 3:28. PMC: 3703528. DOI: 10.3389/fcimb.2013.00028. View

4.
Li J, Claudi B, Fanous J, Chicherova N, Cianfanelli F, Campbell R . Tissue compartmentalization enables persistence during chemotherapy. Proc Natl Acad Sci U S A. 2021; 118(51). PMC: 8713819. DOI: 10.1073/pnas.2113951118. View

5.
Grant S, Hung D . Persistent bacterial infections, antibiotic tolerance, and the oxidative stress response. Virulence. 2013; 4(4):273-83. PMC: 3710330. DOI: 10.4161/viru.23987. View